Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Scholar Rock Holding (SRRK) Long-Term Debt Repayments (2017 - 2026)

Scholar Rock Holding's quarterly Long-Term Debt Repayments came in at $103.1 million in Q1 2026, up 303.83% year-on-year from $25.5 million in Q1 2025, and up 303.83% quarter-over-quarter from $25.5 million in Q1 2025.

Scholar Rock Holding has reported Long-Term Debt Repayments for 5 years, with the latest figure at $103.1 million in Q1 2026.

  • For the quarter ending Q1 2026, Long-Term Debt Repayments rose 303.83% year-over-year to $103.1 million; the trailing twelve-month figure through Mar 2026 stood at $103.1 million (up 300.72% YoY), and the FY2025 full-year result was $25.5 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q1 2026 stood at $103.1 million, up from $25.5 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $103.1 million in Q1 2026, with the low at $25.5 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Scholar Rock Holding 500.61 Mn 20.67 Mn - 103.06 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 103.06 Mn
Mar 31, 2026 103.06 Mn
Mar 31, 2025 25.52 Mn
Mar 31, 2025 25.52 Mn
Jun 30, 2019 198,000.00
Jun 30, 2019 198,000.00
Mar 31, 2019 167,000.00
Mar 31, 2019 167,000.00
Dec 31, 2018 167,000.00
Dec 31, 2018 167,000.00
Sep 30, 2018 167,000.00
Sep 30, 2018 167,000.00
Jun 30, 2018 166,000.00
Jun 30, 2018 166,000.00
Mar 31, 2018 167,000.00
Mar 31, 2018 167,000.00
Dec 31, 2017 167,000.00
Dec 31, 2017 167,000.00
Sep 30, 2017 167,000.00
Sep 30, 2017 167,000.00